Elon Musk says Neuralink has implanted its device in a second trial patient, who had a spinal cord injury, and 400 of the implant's 1,024 electrodes are working
Neuralink has successfully implanted in a second patient its device designed to give paralyzed patients the ability …
Context & Ripple Effects
Neuralink’s human study began with enrollment for paralysis patients in 2023, then moved to a first reported human implant in January. The program was designed as a small, multiyear trial rather than a broad clinical rollout.
The company subsequently received FDA clearance to proceed with a second implant after proposed changes, including deeper embedding of the device’s wires. This update is therefore an early read on whether the revised procedure can be repeated in another participant.
First-order effects
- Neuralink has added a second spinal-cord-injury participant to its human trial, expanding the evidence base beyond its initial implant.
- Only 400 of 1,024 electrodes are reported to be working in this participant, making electrode performance a central technical constraint for the current device and trial team.
Second-order effects
- The partial electrode result puts greater weight on Neuralink’s surgical and hardware refinements as it evaluates repeatability after the FDA-approved changes.
- For prospective trial participants and regulators, subsequent assessments will need to distinguish successful implantation from sustained device functionality and practical user control.
Third-order effects
- If repeat implants produce durable, usable signal performance, brain-computer interface development could shift from single-patient demonstrations toward evidence on manufacturing consistency, surgical reliability, and follow-up care.
- If functionality varies materially across implants, the field’s bottleneck may remain long-term implant reliability rather than simply getting devices into patients; this small trial cannot yet resolve that question.
The trend: This is one data point in the transition of implanted brain-computer interfaces from first-in-human milestones to repeatability and durability testing in tightly controlled trials.